Investors

iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital, Google Ventures, SR One, FinTech Global Capital, Mitsubishi UFJ Capital, Biogen Idec New Ventures, and ATEL Ventures, who have provided a total of $60 million in financing. These firms have exceptional track records in identifying cutting-edge technologies and nurturing the growth of companies that establish leading positions in emerging fields.


	Kleiner Perkins Caufield & Byers http://www.kpcb.com/ Kleiner Perkins Caufield & Byers are passionately committed to helping their portfolio companies succeed. KPCB has built a powerful network of scientists, executives, policy experts and business development activities so that we can help young companies translate their dreams from "bench to bedside" faster and more effectively.
	Highland Capital Partners http://www.hcp.com/ Highland Capital Partners is focused on helping great people build great companies. HCP emphasizes a team-oriented approach in providing the right mix of strategic guidance, hands-on leadership and deep industry domain expertise in helping entrepreneurs and their teams to become market-leading organizations.
	MPM Capital http://www.mpmcapital.com/ MPM focuses equally on capturing and creating value. MPM captures value by identifying under-appreciated assets and by understanding risk. MPM "creates" value by doing whatever it takes to help their companies succeed.
	Google Ventures http://www.google.com/ventures/index.html Google Ventures is Google's venture capital arm, investing across all sectors and in all stages of a company's growth. The diverse experience of the Google Ventures team, coupled with the skills and resources of Google infrastructure and employees, provide a significant advantage in building disruptive and innovative companies.
	SR One http://www.ipierian.com/www.srone.com SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested in more than 135 companies.
	FinTech Global Capital http://www.fgi.co.jp/english/ FinTech Global Capital (FGC) is a Tokyo based venture capital firm founded in 2006 by a team of accomplished investment professionals with extensive industry background. FGC is dedicated to investing in technology companies both in life sciences and information technology with a strong Asian angle.
	Mitsubishi UFJ Capital http://www.mucap.co.jp/english/profile.html Mitsubishi UFJ Capital is the venture capital arm of Mitsubishi UFJ Financial Group Inc (NYSE:MTU), which is one of the world's largest financial services firms.
	Biogen Idec New Ventures http://www.ipierian.com/www.biogenidec.com/site/new-ventures.html New Ventures is Biogen Idec's corporate venture group, which has a commitment of US$200 million for strategic investments in emerging biotech companies. The strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently.
	Mission Bay Capital http://missionbaycapital.com/ Mission Bay Capital, LLC, is a seed-stage venture firm focused on making pivotal investments in bioscience companies emerging from the University of California. We begin with the conviction that more of the creativity of the University of California can directly benefit society. Universities have an obligation to meet public needs for new sources of energy, new solutions for patients, and ultimately the formation of whole new industries, and MBC seeks to accelerate these opportunities.
	ATEL Ventures http://www.atel.com/venture/ ATEL Ventures, Inc., a division of ATEL Capital Group, provides equipment financing, venture debt and equity financing to emerging growth companies. ATEL has an entrepreneurial team with accessible decision makers ready to be responsive to the needs of start-up and growth stage companies.